JP7390317B2 - 抗Ｔｉｅ２抗体およびその使用 - Google Patents

抗Ｔｉｅ２抗体およびその使用 Download PDF

Info

Publication number
JP7390317B2
JP7390317B2 JP2020567832A JP2020567832A JP7390317B2 JP 7390317 B2 JP7390317 B2 JP 7390317B2 JP 2020567832 A JP2020567832 A JP 2020567832A JP 2020567832 A JP2020567832 A JP 2020567832A JP 7390317 B2 JP7390317 B2 JP 7390317B2
Authority
JP
Japan
Prior art keywords
cancer
antibody
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020567832A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526801A (ja
JP2021526801A5 (https=
Inventor
コ・グヨン
ペ・チョミル
キム・ジェリョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Basic Science
Original Assignee
Institute for Basic Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Basic Science filed Critical Institute for Basic Science
Priority claimed from PCT/KR2019/006820 external-priority patent/WO2019235856A1/ko
Publication of JP2021526801A publication Critical patent/JP2021526801A/ja
Publication of JP2021526801A5 publication Critical patent/JP2021526801A5/ja
Priority to JP2023150164A priority Critical patent/JP7700189B2/ja
Application granted granted Critical
Publication of JP7390317B2 publication Critical patent/JP7390317B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020567832A 2018-06-07 2019-06-05 抗Ｔｉｅ２抗体およびその使用 Active JP7390317B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023150164A JP7700189B2 (ja) 2018-06-07 2023-09-15 抗Ｔｉｅ２抗体およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862682042P 2018-06-07 2018-06-07
US62/682,042 2018-06-07
KR10-2019-0066622 2019-06-05
PCT/KR2019/006820 WO2019235856A1 (ko) 2018-06-07 2019-06-05 Tie2에 결합하는 항체 및 이의 용도
KR1020190066622A KR102898574B1 (ko) 2018-06-07 2019-06-05 Tie2에 결합하는 항체 및 이의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023150164A Division JP7700189B2 (ja) 2018-06-07 2023-09-15 抗Ｔｉｅ２抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2021526801A JP2021526801A (ja) 2021-10-11
JP2021526801A5 JP2021526801A5 (https=) 2022-05-31
JP7390317B2 true JP7390317B2 (ja) 2023-12-01

Family

ID=69056780

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020567832A Active JP7390317B2 (ja) 2018-06-07 2019-06-05 抗Ｔｉｅ２抗体およびその使用
JP2023150164A Active JP7700189B2 (ja) 2018-06-07 2023-09-15 抗Ｔｉｅ２抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023150164A Active JP7700189B2 (ja) 2018-06-07 2023-09-15 抗Ｔｉｅ２抗体およびその使用

Country Status (7)

Country Link
US (2) US12024562B2 (https=)
EP (2) EP3805265A4 (https=)
JP (2) JP7390317B2 (https=)
KR (1) KR102898574B1 (https=)
CN (1) CN112399975B (https=)
AU (2) AU2019283520A1 (https=)
CA (1) CA3101506A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7447144B2 (ja) * 2019-08-14 2024-03-11 ファームアブシン・インコーポレイテッド 抗ｔｉｅ２抗体及びその用途
AU2021242249A1 (en) * 2020-03-24 2022-08-18 Genentech, Inc. Tie2-binding agents and methods of use
KR102899889B1 (ko) * 2020-11-03 2025-12-18 한국생명공학연구원 신규 항-Tie2 항체 또는 이의 항원 결합 단편, 및 이의 용도
WO2022235090A1 (ko) * 2021-05-06 2022-11-10 기초과학연구원 Tie2 작용제 항체 및 이의 용도
KR20250005053A (ko) * 2022-01-13 2025-01-09 인제니아 테라퓨틱스 인크. Vegf 및 tie2-결합 융합 단백질 및 그의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525934A (ja) 2011-08-19 2014-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｔｉｅ２抗体およびその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM379494A0 (en) * 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - ii
AU689232B2 (en) * 1994-02-10 1998-03-26 Ludwig Institute For Cancer Research An immunointeractive molecule which binds the (TIE)2/TEK receptor extracellular domain
JP2000041675A (ja) * 1998-07-31 2000-02-15 Nichirei Corp ヒトｔｅｋに対する抗体
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US20090137416A1 (en) * 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20040101920A1 (en) * 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
JP2011102273A (ja) 2009-11-11 2011-05-26 Shiseido Co Ltd Ｔｉｅ２活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤
US10316105B2 (en) 2011-08-19 2019-06-11 Regeneron Pharmaceuticals, Inc. Anti-TIE2 antibodies and uses thereof
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
JP6346761B2 (ja) 2014-03-07 2018-06-20 丸善製薬株式会社 Ｔｉｅ２活性化剤、並びに医薬品組成物、及び経口組成物
JP6699551B2 (ja) * 2014-07-15 2020-05-27 アステラス製薬株式会社 新規抗ヒトＴｉｅ２抗体
CN106994185B (zh) * 2016-01-22 2021-04-06 何玉龙 Tie2对视网膜及其他组织中静脉血管的保护作用及应用
JP2018043949A (ja) 2016-09-15 2018-03-22 サンスター株式会社 Ｔｉｅ２活性用組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525934A (ja) 2011-08-19 2014-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｔｉｅ２抗体およびその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cardiovascular Research，2001年，Vol. 49，pp. 659-670
PNAS，2017年，Vol.114, No. 17，pp. 4382-4387

Also Published As

Publication number Publication date
EP3805265A1 (en) 2021-04-14
EP4591878A3 (en) 2025-10-22
KR20190139148A (ko) 2019-12-17
JP7700189B2 (ja) 2025-06-30
AU2026202090A1 (en) 2026-04-09
KR102898574B1 (ko) 2025-12-09
EP3805265A4 (en) 2022-07-06
US20250011438A1 (en) 2025-01-09
US12024562B2 (en) 2024-07-02
CA3101506A1 (en) 2019-12-12
JP2021526801A (ja) 2021-10-11
EP4591878A2 (en) 2025-07-30
JP2023175830A (ja) 2023-12-12
US20210179719A1 (en) 2021-06-17
CN112399975B (zh) 2024-05-17
CN112399975A (zh) 2021-02-23
AU2019283520A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
JP7700189B2 (ja) 抗Ｔｉｅ２抗体およびその使用
JP7366068B2 (ja) 抗アンジオポエチン２抗体およびその使用
IL259832A (en) Antibodies neutralize hiv
JP2020503258A (ja) Ａｓｃｔ２特異的結合分子及びその使用
JP2022028654A (ja) Ｖｅｇｆ－ｇｒａｂタンパク質と薬物の結合体及びその用途
JP2018535674A (ja) Ａｓｃｔ２特異的結合分子及びその使用
US20150368329A1 (en) Methods of Treating Ocular Diseases
WO2019164219A1 (en) Anti-angiopoietin-2 antibodies and uses thereof
CA3234463A1 (en) Antibodies to pmel17 and conjugates thereof
TW202346354A (zh) 抗ceacam5抗體及其結合物及用途
IL323270A (en) Antibody against PTK7 and its uses
WO2019235856A1 (ko) Tie2에 결합하는 항체 및 이의 용도
HK40130178A (en) Antibody binding to tie2 and use thereof
HK40115552A (zh) 抗ptk7抗体及其用途
WO2025039809A1 (zh) 抗ror1抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230915

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231120

R150 Certificate of patent or registration of utility model

Ref document number: 7390317

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150